Scilex Holding Co

NASDAQ:SCLXUnited States

Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.

Contact Information

Headquarters

960 San Antonio RoadPALO ALTO, CA, United States 94303

Phone

650-516-4310

Fax

302-636-5454

Executives

Executive Chairman of the Board

Henry Ji

President, Chief Executive Officer, Director

Jaisim Shah

Chief Financial Officer, Chief Business Officer, Executive Vice President, Secretary

Elizabeth Czerepak

Director

Dorman Followwill

Director

Laura Hamill